SCHEMBL21613490

SCHEMBL21613490

C=Cc1ncc(-c2ccccc2)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB5 P28074 1/20 0.46
▸ MAP4K4 O95819 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ PDGFRB P09619 2/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ AXL P30530 2/20 0.38
▸ CDK8 P49336 2/20 0.38
▸ KDR P35968 2/20 0.38
▸ FLT3 P36888 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23319684 0.85 MAP4K4 (0.44) PSMB5MAP4K4RAB9ATDP1
SCHEMBL24011937 0.83 PDGFRB (0.43) MAP4K4PDGFRBPDGFRAGSK3BPIM1
SCHEMBL24011728 0.82 ESR2 (0.47) MAP4K4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL23319558 0.81 PSMB5 (0.43) PSMB5MAP4K4MAPTCASP1L3MBTL1
SCHEMBL21613445 0.81 PSMB5 (0.45) PSMB5MAP4K4MAPTCASP1NPC1
SCHEMBL21613442 0.79 PSMB5 (0.44) PSMB5MAP4K4MAPTCASP1NPC1
SCHEMBL18136475 0.75 PSMB5 (0.53) PSMB5MAP4K4MAPTCASP1NPC1
SCHEMBL23280655 0.74 PRMT5 (0.34) MAP4K4PDGFRBPDGFRAAXL
SCHEMBL24229449 0.74 PDGFRB (0.43) MAP4K4PDGFRBPDGFRABLKCSNK1G2
SCHEMBL10205844 0.73 PSMB5 (0.51) PSMB5MAP4K4MAPTCASP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3319963-B1 SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-01-08 — — EP disclosed
Send feedback